Kodiak Sciences Chairman and CEO Victor Perlroth Receives Stock Option Grant

Executive Compensation Structure at Kodiak Sciences

Victor Perlroth, serving as Chairman and CEO of Kodiak Sciences, received equity compensation through a stock option grant filed with regulators on July 17, 2026. The grant represents a common practice among public company executives, where stock options align leadership incentives with shareholder returns. The option grant of 100,000 shares at $42.42 per share reflects the company's approach to long-term executive retention and performance alignment through equity participation in the company's future value.

The filing reveals that Perlroth maintains multiple relationships with Kodiak Sciences beyond his executive role. In addition to serving as Chairman and CEO, he holds positions as a company director and maintains beneficial ownership of at least 10% of the company's outstanding shares. This concentration of roles and ownership stake suggests significant personal alignment with the company's strategic direction and shareholder interests, a structure that may be relevant to investors evaluating governance and leadership commitment at the firm.

Vesting Schedule and Service Requirements

The stock options granted to Perlroth follow a structured vesting schedule spanning approximately four years. According to the filing, one forty-eighth of the shares will vest one month after July 1, 2026, with the remaining shares vesting through 47 successive equal monthly installments thereafter. This tiered approach distributes the equity grant across a multi-year period, a common practice designed to encourage continued executive service and commitment to long-term company performance.

Vesting of the options is contingent upon what the filing describes as "Continuous Service" as defined in Kodiak Sciences' 2018 Equity Incentive Plan. This condition means that Perlroth must maintain his employment or service relationship with the company to realize the full benefit of the grant. The specific definition of Continuous Service under the plan framework is referenced but not detailed in the regulatory filing itself, though such plans typically consider various employment statuses and circumstances that might affect vesting eligibility.

Exercise Price and Grant Timing

The stock options were granted at an exercise price of $42.42 per share, established as of the transaction date of July 15, 2026. The exercise price represents the fixed cost at which Perlroth may purchase shares underlying the options at any point until the expiration date of July 14, 2036. This ten-year exercise window provides substantial time flexibility for the executive to determine optimal timing for converting options into company shares, should market conditions and personal circumstances warrant such action.

The filing does not disclose specific information regarding the Kodiak Sciences stock price at the time of grant or how the $42.42 exercise price compares to the company's trading valuation on July 15, 2026. The immediate share price impact was not clear from available public information. Investors interested in assessing the grant's economic context relative to market conditions at the time would need to cross-reference historical stock price data from additional sources.

Beneficial Ownership Following the Grant

Following the transaction reported in the filing, Perlroth will beneficially own 100,000 option shares on a direct basis, according to the disclosure. The filing indicates that the options represent direct beneficial ownership of the underlying securities, meaning Perlroth owns them in his individual capacity rather than through intermediary entities or trusts. However, the filing does not provide comprehensive detail regarding his total beneficial ownership position in Kodiak Sciences, including both vested and unvested equity holdings.

The filing confirms that Perlroth's status as a 10% owner of the company places him in a category requiring enhanced disclosure obligations under securities regulations. This threshold ownership level subjects significant transactions and holdings changes to public reporting requirements, ensuring transparency for investors regarding substantial shareholder activity and interests. The combination of his CEO, director, and 10% owner roles creates a significant alignment of personal financial interests with shareholder outcomes.

Kodiak Sciences 2018 Equity Incentive Plan Framework

The stock option grant operates under the terms of Kodiak Sciences' 2018 Equity Incentive Plan, a comprehensive framework governing equity compensation throughout the organization. The plan establishes vesting schedules, service conditions, exercise terms, and other parameters governing options and other equity instruments granted to executives, employees, and other service providers. The specific vesting schedule adopted for Perlroth's grant—with the one forty-eighth initial tranche followed by 47 equal monthly installments—reflects customized terms potentially tied to the individual role, seniority, or grant date.

The use of the Continuous Service definition as the vesting condition represents a standard approach in equity plans, establishing clarity around which employment circumstances permit ongoing vesting and which might trigger acceleration, forfeiture, or other consequences. The filing does not elaborate on whether the plan includes acceleration provisions in change-of-control scenarios, acceleration for disability or retirement, or other contingencies that might affect vesting outside the standard monthly schedule. Investors seeking detailed plan mechanics would need to review the full plan document filed separately with regulators.

Regulatory Filing and Signature Authority

The regulatory filing was executed by David Peinsipp, identified as an attorney-in-fact for Victor Perlroth, and dated July 17, 2026. The use of an attorney-in-fact to sign the disclosure form is a standard practice that allows executives to delegate signature authority for regulatory filings to legal counsel or other authorized representatives. The filing date of July 17, 2026 represents two days after the transaction date of July 15, 2026, aligning with regulatory requirements for prompt reporting of beneficial ownership changes by company insiders.

The document carries the standard SEC warnings regarding the criminal penalties associated with intentional misstatements or omissions of material facts in beneficial ownership disclosures. These disclosures form part of the broader regulatory framework requiring officers, directors, and significant shareholders to report transactions and holdings changes, supporting market transparency and investor protection. The filing's completion indicates compliance with Section 16(a) of the Securities Exchange Act of 1934, which governs insider reporting obligations for equity securities transactions.

Implications for Investor Monitoring

The grant of 100,000 options to Perlroth represents a significant equity compensation event at Kodiak Sciences, particularly given his already substantial ownership stake as a 10% shareholder. Investors tracking insider equity activity may view such grants as evidence of the company's confidence in retaining executive leadership and aligning management incentives with long-term shareholder value creation. The multi-year vesting schedule also signals management's expectation of continued operational focus and strategic execution over the four-year grant period.

The filing provides a snapshot of insider transactions and holdings at a specific point in time but does not offer guidance regarding future grants, compensation strategy, or executive retention plans. Investors seeking broader context on Kodiak Sciences' compensation practices, equity plan utilization, and management incentive philosophy would benefit from reviewing additional disclosures such as proxy statements and annual equity plan reports. The concentration of roles and ownership in Perlroth's hands—as CEO, director, and 10% owner—remains relevant to governance considerations and decision-making dynamics at the board and shareholder levels.

No Further Transactions or Amendments Indicated

The filing reports a single transaction dated July 15, 2026, with no indication of amendments to prior disclosures or multiple reportable events. The document structure suggests this represents a straightforward grant event rather than a modification of previously disclosed holdings or an amendment to an earlier filing. The filing does not reference any concurrent transactions, dispositions, or other equity activity requiring separate disclosure, indicating this stock option grant stands as the sole reportable event in this period.

The straightforward nature of the filing—a single option grant with standard vesting terms—contrasts with more complex insider transactions that might involve dispositions, exercises, or strategic equity maneuvers. The absence of multiple transactions or amendments suggests routine executive compensation activity consistent with normal corporate governance and equity plan administration at Kodiak Sciences. Investors monitoring insider activity trends over time would need to review subsequent filings to assess patterns in executive compensation, equity grants, or securities transactions.